Intellia Therapeutics, Inc. (NASDAQ:NTLA) has recently announced its anticipated 2025 milestones and a strategic reorganization to prioritize the advancement of its late-stage programs, NTLA-2002 and Nexiguran Ziclumeran (Nex-Z). The company's phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE) is expected to complete enrollment in the second half of 2025, with plans to submit a biologics license application in the second half of 2026.
More than 550 patients are expected to be enrolled by the year-end within the ongoing Magnitude study for Nex-Z in ATTR-CM, with the program remaining ahead of internal enrollment estimates. The company has also announced a net workforce reduction of approximately 27% in 2025, which is anticipated to support company operations into the first half of 2027 and through the anticipated first commercial launch in the U.S.
As of the end of the fourth quarter of 2024, Intellia ended with approximately $862 million in cash, cash equivalents, and investments. The combination of its cash balance and anticipated cost savings is expected to provide the company with cash runway into the first half of 2027.
The company announced the retirement of Laura Sepp-Lorenzino, Ph.D., Intellia’s Chief Scientific Officer, effective December 31, 2025, after more than 30 years of service in the biopharmaceutical industry and academia. Dr. Sepp-Lorenzino will transition from her role as CSO and continue as a senior scientific advisor for the remainder of the year. Additionally, Birgit Schultes, Ph.D., who has been leading immunology and cell therapy since 2017, will be promoted to Executive Vice President and Chief Scientific Officer, effective January 13, 2025.
Intellia’s strategic priorities reflect the company’s ongoing evolution from a late-stage development company to a commercial-ready organization by the end of 2026. The company aims to drive focused clinical execution to complete or accelerate enrollment in the pivotal studies of NTLA-2002 and Nex-Z and advance commercial readiness by implementing core commercialization and medical capabilities for an initial launch in the U.S.
John Leonard, M.D., President, and Chief Executive Officer of Intellia, is scheduled to present a company overview at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13. A live webcast will be available through the events and presentations page of the investors & media section on Intellia’s website, www.intelliatx.com.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. As a result of these announcements, the company's shares have moved -17.0% on the market, and are now trading at a price of $9.98. If you want to know more, read the company's complete 8-K report here.
